If you are interested in T-CALM, click here to find a site near you.

T-Calm Study
Study Sponsor: Cavion
20 September 2017

Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor

Introducing a new therapeutic approach for patients with movement disorders

Cavion, Inc. announced today that the first patient has been enrolled in its new T-CALM Study (Tremor Cav3 Modulation Study), a Phase 2 clinical trial using the company’s T-type calcium channel modulator CX-8998 for patients with Essential Tremor (ET).

Read More


Press Releases